Link: https://links.sgx.com/1.0.0/corporate-announcements/UF5EILADLBZZF62I/c0a92e5bf1e19eb2b85071cb65161f57751cd5fe3b7f490fe96239ffce200a67

Summary:

• Group revenue for Q1 ended 30 September 2025 reached RM 100.5 million, up 23% compared to the same period last year, driven by higher patient volumes across all admission categories.

• Profit before tax rose sharply by 47% year-on-year to RM 6.6 million, supported by strong performance in Oncology and reduced corporate customer discounts at Thomson Hospital Kota Damansara.

• Net profit attributable to owners was RM 4.4 million, with basic earnings per share at 0.25 sen, up from 0.17 sen the previous year.

• Total assets held steady at RM 1.13 billion, with equity increasing to RM 857.5 million.

• Strong cash management: Net increase in cash and cash equivalents for the quarter was RM 17.4 million, ending at RM 78.2 million.

• No dividends were paid and no new corporate proposals or material litigation events noted in the quarter.

• Management remains optimistic for FY2026, expecting growth from expanded capacity, ongoing expansion of specialties, and efforts to further diversify and strengthen corporate and international patient base.

• Group continues to monitor supply chain risks due to global economic uncertainties but reports no material impact so far.

• No significant related party transactions or contingent liabilities were reported for the quarter.